Team:LCG-UNAM-Mexico/Safety
From 2009.igem.org
(Difference between revisions)
(→Safety) |
(→Safety) |
||
Line 20: | Line 20: | ||
They think this risk is latent but you can maintain P2 apart from the population and you can screen for the resistance periodically. So, it is possible to control this safety issue. About the E3 toxin they told us that in the laboratory conditions it is not a problem because you work in a restricted environment.<br><br> | They think this risk is latent but you can maintain P2 apart from the population and you can screen for the resistance periodically. So, it is possible to control this safety issue. About the E3 toxin they told us that in the laboratory conditions it is not a problem because you work in a restricted environment.<br><br> | ||
- | In some literature we have found E3 colicin is able to recognize and cut mouse and HeLa ribosomes[[Team:LCG-UNAM-Mexico/Safety#References|1]] however in other studies they ensure low dosis of these toxin are not so hazardous because of the immune system [[Team:LCG-UNAM-Mexico/Safety#References|2]]. In fact, in a third source they mention this toxin could be used as an anticarcinogenic drug because cancer cells are much more damaged by colicin E3 than normal ones.[[Team:LCG-UNAM-Mexico/Safety#References|3]]<br><br> | + | In some literature we have found E3 colicin is able to recognize and cut mouse and HeLa ribosomes[[Team:LCG-UNAM-Mexico/Safety#References|(1)]] however in other studies they ensure low dosis of these toxin are not so hazardous because of the immune system [[Team:LCG-UNAM-Mexico/Safety#References|(2)]]. In fact, in a third source they mention this toxin could be used as an anticarcinogenic drug because cancer cells are much more damaged by colicin E3 than normal ones.[[Team:LCG-UNAM-Mexico/Safety#References|(3)]]<br><br> |
- | Do any of the new BioBrick parts that you made this year raise any safety issues? | + | Do any of the new BioBrick parts that you made this year raise any safety issues? Yes, the E3 colicin. <br> |
- | o If yes, did you document these issues in the Registry? | + | o If yes, did you document these issues in the Registry? Yes, we will<br> |
==References== | ==References== |
Latest revision as of 03:55, 22 October 2009